MARKET

EXEL

EXEL

Exelixis Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

17.76
+0.32
+1.83%
After Hours: 17.96 +0.2 +1.13% 17:11 05/20 EDT
OPEN
17.56
PREV CLOSE
17.44
HIGH
17.80
LOW
17.17
VOLUME
4.52M
TURNOVER
0
52 WEEK HIGH
24.75
52 WEEK LOW
15.50
MARKET CAP
5.70B
P/E (TTM)
19.25
1D
5D
1M
3M
1Y
5Y
12 Health Care Stocks Moving In Thursday's Intraday Session
 
Benzinga · 2d ago
CIG, BTCM and CYAD among mid-day movers
Gainers: NeuroMetrix (NURO) +34%. Millicom International (TIGO) +32%. Grab Holdings (GRAB) +30%. SIGA Technologies (SIGA) +26%. Celyad Oncology (CYAD) +19%. Clene (CLNN) +19%. Applied Blockchain (APLD) +19%. Immunome (IMNM) +18%.
Seekingalpha · 3d ago
Exelixis drops quickly on day four of Cabometyx patent trial
Exelixis (NASDAQ:EXEL) plunged 14% during day four of the  Cabometyx patent trial. Developing story ...
Seekingalpha · 3d ago
Exelixis (EXEL) Q1 Earnings Beat, Revenues Miss Estimates
Exelixis (EXEL) beats on earnings but misses on revenues in the first quarter. While the top line increases on a year-over-year basis, the bottom line improves from the year-ago breakeven figure.
Zacks · 05/11 18:08
Exelixis Q1 net income surges nearly 42 times higher on strong Cabometyx sales
Exelixis saw its Q1 net income increase nearly 42 times higher year over year -- $68.6M compared to $1.6M -- helped in large part by a strong boost in sales
Seekingalpha · 05/10 22:59
Exelixis (EXEL) Tops Q1 Earnings Estimates
Exelixis (EXEL) delivered earnings and revenue surprises of 50% and 6.02%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 05/10 21:25
Exelixis: Q1 Earnings Insights
Exelixis (NASDAQ:EXEL) reported its Q1 earnings results on Tuesday, May 10, 2022 at 04:05 PM. Here's what investors need to know about the announcement. Earnings Exelixis beat estimated earnings by 85.71%, reporting an EPS of $0.26 versus an estimate of $0...
Benzinga · 05/10 21:08
Exelixis Q1 EPS $0.26 Beats $0.14 Estimate, Sales $355.98M Miss $372.46M Estimate
Exelixis (NASDAQ:EXEL) reported quarterly earnings of $0.26 per share which beat the analyst consensus estimate of $0.14 by 85.71 percent. This is a 188.89 percent increase over earnings of $0.09 per share from the same
Benzinga · 05/10 20:35
More
No Data
Learn about the latest financial forecast of EXEL. Analyze the recent business situations of Exelixis Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 13 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

38.46%Strong Buy
38.46%Buy
15.38%Hold
7.69%Under-perform
0.00%Sell
Analyst Price Target
The average EXEL stock price target is 27.17 with a high estimate of 35.00 and a low estimate of 19.00.
High35.00
Average27.17
Low19.00
Current 17.76
EPS
Actual
Estimate
0.080.150.220.30
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Institutional Holdings
Institutions: 528
Institutional Holdings: 297.33M
% Owned: 92.70%
Shares Outstanding: 320.74M
TypeInstitutionsShares
Increased
117
15.52M
New
68
4.93M
Decreased
108
16.51M
Sold Out
34
1.22M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.64%
Pharmaceuticals & Medical Research
+1.63%
Key Executives
Non-Executive Chairman/Independent Director
Stelios Papadopoulos
Chief Executive Officer/President/Director
Michael Morrissey
Chief Financial Officer/Executive Vice President
Christopher Senner
Executive Vice President/Chief Scientific Officer
Peter Lamb
Executive Vice President/General Counsel/Secretary
Jeffrey Hessekiel
Executive Vice President
Vicki Goodman
Executive Vice President
Patrick Haley
Independent Director
Charles Cohen
Independent Director
Carl Feldbaum
Independent Director
Maria Freire
Independent Director
Alan Garber
Independent Director
Vincent Marchesi
Independent Director
George Poste
Independent Director
Julie Smith
Independent Director
Lance Willsey
Independent Director
Jacqueline Wright
Independent Director
Jack Wyszomierski
No Data
No Data
About EXEL
Exelixis, Inc. is an oncology focused biotechnology company. The Company is engaged in the discovery, development and commercialization of medicines to treat cancers. Its platform also provides therapies to cancer patients with additional treatment options. The Company's cabozantinib molecule, is an inhibitor of multiple tyrosine kinases including MET, AXL, VEGF receptors and RET. The products derived from cabozantinib are CABOMETYX tablets for renal cell carcinoma (RCC) and COMETRIQ capsules for progressive, metastatic medullary thyroid cancer (MTC). Its other two product candidates are COTELLIC (cobimetinib), is an inhibitor of MEK with multiple combination regimens to treat specific forms of advanced melanoma and MINNEBRO (esaxerenone), is an oral, non-steroidal, selective blocker of the mineralocorticoid receptor (MR) for the treatment of hypertension. Its phase I b clinical trial programs include XL092, STELLAR-001 and STELLAR-002.

Webull offers kinds of Exelixis, Inc. stock information, including NASDAQ:EXEL real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, EXEL stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading EXEL stock methods without spending real money on the virtual paper trading platform.